Repligen Co. (NASDAQ:RGEN) Stake Raised by T. Rowe Price Investment Management Inc.

T. Rowe Price Investment Management Inc. boosted its stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 474.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 159,057 shares of the biotechnology company's stock after acquiring an additional 131,347 shares during the quarter. T. Rowe Price Investment Management Inc. owned about 0.28% of Repligen worth $22,895,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of RGEN. Signaturefd LLC grew its position in Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 124 shares during the last quarter. Sava Infond d.o.o. purchased a new position in Repligen in the fourth quarter valued at about $29,000. UMB Bank n.a. boosted its stake in Repligen by 49.1% in the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock valued at $48,000 after acquiring an additional 110 shares in the last quarter. Global Retirement Partners LLC increased its position in Repligen by 54.0% during the 4th quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock valued at $53,000 after buying an additional 129 shares in the last quarter. Finally, Pilgrim Partners Asia Pte Ltd acquired a new position in shares of Repligen during the fourth quarter valued at about $55,000. Institutional investors own 97.64% of the company's stock.

Repligen Stock Down 0.6 %

Shares of RGEN traded down $0.79 during mid-day trading on Thursday, reaching $137.20. 481,717 shares of the stock traded hands, compared to its average volume of 718,897. The firm has a market cap of $7.70 billion, a price-to-earnings ratio of -269.02, a P/E/G ratio of 4.54 and a beta of 1.27. The stock has a fifty day simple moving average of $138.77 and a 200 day simple moving average of $145.87. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen Co. has a 12-month low of $102.97 and a 12-month high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, beating analysts' consensus estimates of $0.35 by $0.04. The firm had revenue of $169.17 million during the quarter, compared to analyst estimates of $163.65 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. Repligen's quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.28 EPS. Sell-side analysts expect that Repligen Co. will post 1.72 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on RGEN. JPMorgan Chase & Co. cut their target price on Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a research report on Tuesday. TD Cowen began coverage on shares of Repligen in a research note on Monday, February 10th. They set a "buy" rating and a $200.00 target price on the stock. Canaccord Genuity Group reduced their price objective on shares of Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research report on Wednesday, April 16th. Wolfe Research upgraded Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 target price on the stock in a research report on Tuesday. Finally, StockNews.com upgraded shares of Repligen from a "sell" rating to a "hold" rating in a research report on Monday. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $173.25.

Insider Buying and Selling

In other news, Director Margaret Pax bought 250 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were purchased at an average cost of $150.69 per share, with a total value of $37,672.50. Following the completion of the acquisition, the director now directly owns 1,043 shares in the company, valued at approximately $157,169.67. The trade was a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.20% of the company's stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.